Martes 29 de septiembre de 2026 · 152 publicaciones en las últimas 24 h · 29 fuentes · actualizado hace 22 min
Lo último en oncología según revistas científicas, autoridades sanitarias y prensa médica.
32 notas · Solo en español
(MedPage Today) -- Local control after surgical removal of large brain metastases improved significantly when patients received fractionated stereotactic radiosurgery (SRS) instead of single-fraction SRS, a randomized trial showed. Surgical-bed...
Representantes del Gobierno, CTIC y academia plantearon la necesidad de convertir las normas y políticas existentes en rutas de atención efectivas.
La Escuela Colombiana de Ingeniería presentó este martes 29 de septiembre Helix-A, una plataforma para la ciencia, la innovación y el desarrollo.
Cinco agentes patógenos son los responsables del 12 por ciento de los diagnósticos tumorales registrados a nivel internacional
Una investigación vinculó 2,3 millones de casos diagnosticados en 2024 con infecciones causadas principalmente por cinco patógenos.
pacientes: La Fundación Jiménez Díaz presenta su modelo para personalizar el tratamiento de leucemias y linfomas
El paciente había sido diagnosticado antes de nacer y pasó casi dos años entre consultas en el país y el exterior. Un equipo multidisciplinario del Hospital Italiano de Buenos Aires extirpó la lesión, ubicada en una zona crítica del ventrículo izquierdo, tras planificar la intervención…
by Po-Huang Chen, Ming-Shen Dai, Mao-Hsuan Huang, Hsin-Yu Chen, Li-Ting Kao, Tina Yi-Jin Hsieh, Hong-Jie Jhou, Cho-Hao Lee Background Preclinical evidence identifies the serotonin transporter (SERT, encoded by SLC6A4) as an immune checkpoint on CD8+ T cells, with selective serotonin reuptake inhibitors (SSRIs) enhancing antitumor…
Un estudio liderado por el Grupo de Inmunoterapia en inmunología de los tumores del Vall d'Hebron Instituto de Oncología (Vhio) ha demostrado que el uso de la biopsia líquida en sangres podría identificar proteínas específicas producidas por las células tumorales, conocidas como neoantígenos, con el…
Administrar radioterapia focalizada en tres a cinco sesiones después de la cirugía para una metástasis cerebral grande logra reducir el riesgo de que el cáncer reaparezca en el sitio quirúrgico en comparación con administrar la radiación en una sola sesión, según los resultados del estudio…
Nature Medicine, Published online: 29 September 2026; doi:10.1038/s41591-026-04693-z In a phase 1 trial, inhibition of the Werner syndrome helicase (WRN) enzyme exploits a new synthetic lethal vulnerability in cancers with microsatellite instability, offering a new way to target these tumors beyond immune checkpoint inhibition.
Nature Medicine, Published online: 29 September 2026; doi:10.1038/s41591-026-04657-3 In the dose-escalation stage of a phase 1 trial evaluating RO7589831, a first-in-class inhibitor of the synthetic lethal target Werner syndrome helicase, in patients with microsatellite instability and/or DNA mismatch repair-deficient solid tumors, the maximum tolerated dose…
Urólogos advierten que levantarse repetidamente durante la noche puede estar relacionado con problemas urinarios que requieren valoración médica.
La Comisión de Salud Pública del Parlamento ha aprobado dos proyectos de informes, uno de ellos del eurodiputado español Nicolás Casares
Nature Medicine, Published online: 28 September 2026; doi:10.1038/d41591-026-00048-w Using data from over 3 million people, researchers trace the ancestral history of the EGFR T790M germline mutation and its present contribution to lung cancer risk in those who never smoked.
Scientists have mapped the genetics of cat cancer on an unprecedented scale and found surprising similarities with tumors in humans. The findings could help bring precision cancer treatments to cats while also revealing new clues about how human cancers develop and respond to drugs.
A new analysis suggests mammograms may lead to far less breast cancer overdiagnosis than some earlier studies indicated. Researchers reexamined all eight major randomized screening trials and accounted for differences in follow-up time, screening frequency, and screening after trials ended. Their results were consistent with…
Researchers used CRISPR to remove CD33 from donor stem cells, potentially giving doctors a way to attack aggressive blood cancers without destroying the healthy cells patients need after a transplant. In a 30-patient trial, the edited cells successfully took hold and appeared to shield blood…
Scientists discovered a surprising backup system that lets mammalian cells make the essential amino acid cysteine even when the pathways once considered indispensable are disabled. The same survival mechanism may help cancer cells resist treatment, raising the possibility that shutting it down could make tumors…
A 70-year-old leukemia drug is still revealing new secrets. Researchers found that removing a protein called NUDT5 protected cells from the drug, even though simply blocking the protein had little effect. The unexpected result points to a hidden cellular role that could help explain why…
A new experimental drug called CS18 may help break through cancer drug resistance by disabling several of the defenses tumors use to survive treatment. It strengthened existing therapies, restored drug sensitivity in resistant lung cancer cells, and slowed tumor growth in animal models.
BackgroundCancer-associated fibroblasts (CAF) are major regulators of the tumor microenvironment (TME), yet the pathways governing CAF function remain incompletely understood. Type 2 deiodinase (DIO2, D2), which converts thyroxine (T4) to the active thyroid hormone triiodothyronine (T3), has not been systematically investigated in CAF across different…
BackgroundNHS-Galleri did not reach its prespecified primary endpoint of a reduction in combined stage III and IV cases, but reported fewer stage IV cancers after annual multi-cancer early detection screening. We estimated the potential five-year life-years associated with the cancer-specific stage IV differences observed during…
Learn the latest U.S. cancer trends, including falling death rates and lung cancer progress.
Prostate cancer has long served as a fertile ground for innovation in cancer therapy. Compared with many other malignancies, localized prostate cancer occupies a unique clinical space. Although the incidence of new diagnoses is high, prostate cancer often follows an indolent natural history, resulting in…
This randomized clinical trial assesses whether stereotactic body radiotherapy is superior to moderately hypofractionated intensity-modulated radiation therapy in terms of patient-reported urinary irritative/obstructive and bowel quality of life and disease-free survival in patients with localized intermediate-risk prostate cancer.
The objective of this study was to assess whether stereotactic body radiotherapy (SBRT) was superior to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for urinary and bowel quality of life and disease-free survival in patients with localized intermediate-risk prostate cancer.
by Brian D. Nicholson, Clare R. Bankhead, Sufen Zhu, Jason Lee Oke, Cynthia Wright Drakesmith, Rafael Perera, Frederick D. Richard Hobbs, Pradeep S. Virdee Background Unexpected weight loss (UWL) is a non-specific cancer symptom. Abnormalities in the most recent blood test contribute to cancer referral…
Scientists are testing a counterintuitive way to fight mesothelioma, an aggressive asbestos-linked cancer with few effective treatments. A new experimental mesothelioma drug kills cancer cells by disabling PRX3, an antioxidant defense that tumors use to survive intense oxidative stress. In an early clinical trial, it…
Scientists discovered a hidden “immune organ” inside the skull that acts as a rapid first responder against brain cancer in mice. Strengthening this local immune defense improved tumor rejection and survival, raising the possibility of new treatments that target the skull directly.
The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting new treatments to patients who need them.
Medicamentos y regulaciónOncologíaSalud de la mujer y embarazo
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.
Mostramos el titular, un extracto breve y el enlace a cada nota; el contenido completo y sus derechos son de cada medio. Las notas se recogen automáticamente de los canales RSS públicos de las fuentes cada 30 minutos y se clasifican por especialidad con palabras clave, así que alguna puede quedar en una sección que no le corresponde. Una noticia no es una recomendación clínica: antes de cambiar una conducta, revisa el artículo original y las guías vigentes. ¿Eres editor de un medio y prefieres no aparecer? Escríbenos. Suscríbete por RSS.